Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

European Innovation Council · Running

VacciNEXT Next generation therapeutic vaccine for targeted cancer treatment

Coordinator
Basinnov Life Sciences Unipessoal Lda, Portugal
Runs
1 October 2026 to 30 September 2029
Status
Running
EU funding
€2.8m
Total cost
€2.8m
Partners
5 organisations in 3 countries
Type
European Innovation Council
Grant agreement
101256947

What the project is doing

In the project's own words, from its summary on CORDIS.

VacciNEXT is a next-generation therapeutic anti-cancer vaccine for targeted stimulation of the immune system against cancer. VacciNEXT offers a paradigm-shifting solution to the persistent challenges of cancer immunotherapy – overcoming tumour tolerance, limited antigenicity, and immunosuppressive microenvironments – through a first-in-class, multifunctional therapeutic vaccine that unites, in a single innovative construct, a rationally designed triple therapeutic action:- an immunogenic protein carrier.- an artificial antigen with improved binding affinity to antibodies, based on an aberrant glycoprotein overexpressed in up to 90% of epithelial cancers (Mucin 1 – MUC1), including gastrointestinal tumours, lung, pancreas and breast cancer.- a small-molecule immunomodulator, which ensures targeted immunostimulation at the tumour site, with reduced side effects.

Our central hypothesis is that integrating tumour-specific antigen presentation and tumour-localised innate immune stimulation within a single, chemically-defined and site-selectively assembled construct will overcome both immune tolerance (enabling potent T-cell responses) and systemic toxicity – limitations that have so far stalled progress in cancer vaccine development. The project aims to propel this deep-tech vaccine from TRL2 into preclinical studies (TRL4).

Under the coordination of Basinnov (expert in Oncology and Immunotherapy), the consortium integrates the expertise in translational biomedical research from GIMM (PT), in biotechnological advancements on antigen synthesis and design from Univ. La Rioja (ES) and in cutting-edge protein engineering from Univ. Cambridge (UK).

Topics

Who is involved

OrganisationCityCountryRole
Basinnov Life Sciences Unipessoal LdaLisboaPortugalCoordinator
Universidad De La RiojaLogronoSpainParticipant
Fhc Farmaceutica SAMortaguaPortugalThird party
Fundacao Gimm - Gulbenkian Institute for Molecular MedicineLisboaPortugalParticipant
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI